Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis

Masahiro Morita, Nadeem Siddiqui, Sakie Katsumura, Christopher Rouya, Ola Larsson, Takeshi Nagashima, Bahareh Hekmatnejad, Akinori Takahashi, Hiroshi Kiyonari, Mengwei Zang, René St-Arnaud, Yuichi Oike, Vincent Giguère, Ivan Topisirovic, Mariko Okada-Hatakeyama, Tadashi Yamamoto, Nahum Sonenberg

Research output: Contribution to journalArticle

Abstract

Whole-body metabolic homeostasis is tightly controlled by hormone-like factors with systemic or paracrine effects that are derived from nonendocrine organs, including adipose tissue (adipokines) and liver (hepatokines). Fibroblast growth factor 21 (FGF21) is a hormone-like protein, which is emerging as a major regulator of whole-body metabolism and has therapeutic potential for treating metabolic syndrome. However, the mechanisms that control FGF21 levels are not fully understood. Herein, we demonstrate that FGF21 production in the liver is regulated via a posttranscriptional network consisting of the CCR4–NOT deadenylase complex and RNA-binding protein tristetraprolin (TTP). In response to nutrient uptake, CCR4–NOT cooperates with TTP to degrade AU-rich mRNAs that encode pivotal metabolic regulators, including FGF21. Disruption of CCR4–NOT activity in the liver, by deletion of the catalytic subunit CNOT6L, increases serum FGF21 levels, which ameliorates diet-induced metabolic disorders and enhances energy expenditure without disrupting bone homeostasis. Taken together, our study describes a hepatic CCR4–NOT/FGF21 axis as a hitherto unrecognized systemic regulator of metabolism and suggests that hepatic CCR4–NOT may serve as a target for devising therapeutic strategies in metabolic syndrome and related morbidities.

Original languageEnglish (US)
Pages (from-to)7973-7981
Number of pages9
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number16
DOIs
StatePublished - Apr 16 2019

Fingerprint

Homeostasis
Liver
Tristetraprolin
Hormones
Adipokines
RNA-Binding Proteins
Energy Metabolism
fibroblast growth factor 21
Adipose Tissue
Catalytic Domain
Diet
Morbidity
Bone and Bones
Messenger RNA
Therapeutics
Serum
Proteins

Keywords

  • CCR4–NOT
  • Deadenylase
  • FGF21
  • Hepatokine
  • Metabolic syndrome

ASJC Scopus subject areas

  • General

Cite this

Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis. / Morita, Masahiro; Siddiqui, Nadeem; Katsumura, Sakie; Rouya, Christopher; Larsson, Ola; Nagashima, Takeshi; Hekmatnejad, Bahareh; Takahashi, Akinori; Kiyonari, Hiroshi; Zang, Mengwei; St-Arnaud, René; Oike, Yuichi; Giguère, Vincent; Topisirovic, Ivan; Okada-Hatakeyama, Mariko; Yamamoto, Tadashi; Sonenberg, Nahum.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 16, 16.04.2019, p. 7973-7981.

Research output: Contribution to journalArticle

Morita, M, Siddiqui, N, Katsumura, S, Rouya, C, Larsson, O, Nagashima, T, Hekmatnejad, B, Takahashi, A, Kiyonari, H, Zang, M, St-Arnaud, R, Oike, Y, Giguère, V, Topisirovic, I, Okada-Hatakeyama, M, Yamamoto, T & Sonenberg, N 2019, 'Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis', Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 16, pp. 7973-7981. https://doi.org/10.1073/pnas.1816023116
Morita, Masahiro ; Siddiqui, Nadeem ; Katsumura, Sakie ; Rouya, Christopher ; Larsson, Ola ; Nagashima, Takeshi ; Hekmatnejad, Bahareh ; Takahashi, Akinori ; Kiyonari, Hiroshi ; Zang, Mengwei ; St-Arnaud, René ; Oike, Yuichi ; Giguère, Vincent ; Topisirovic, Ivan ; Okada-Hatakeyama, Mariko ; Yamamoto, Tadashi ; Sonenberg, Nahum. / Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 16. pp. 7973-7981.
@article{0c4c13edae104bc486af4d51667118fe,
title = "Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis",
abstract = "Whole-body metabolic homeostasis is tightly controlled by hormone-like factors with systemic or paracrine effects that are derived from nonendocrine organs, including adipose tissue (adipokines) and liver (hepatokines). Fibroblast growth factor 21 (FGF21) is a hormone-like protein, which is emerging as a major regulator of whole-body metabolism and has therapeutic potential for treating metabolic syndrome. However, the mechanisms that control FGF21 levels are not fully understood. Herein, we demonstrate that FGF21 production in the liver is regulated via a posttranscriptional network consisting of the CCR4–NOT deadenylase complex and RNA-binding protein tristetraprolin (TTP). In response to nutrient uptake, CCR4–NOT cooperates with TTP to degrade AU-rich mRNAs that encode pivotal metabolic regulators, including FGF21. Disruption of CCR4–NOT activity in the liver, by deletion of the catalytic subunit CNOT6L, increases serum FGF21 levels, which ameliorates diet-induced metabolic disorders and enhances energy expenditure without disrupting bone homeostasis. Taken together, our study describes a hepatic CCR4–NOT/FGF21 axis as a hitherto unrecognized systemic regulator of metabolism and suggests that hepatic CCR4–NOT may serve as a target for devising therapeutic strategies in metabolic syndrome and related morbidities.",
keywords = "CCR4–NOT, Deadenylase, FGF21, Hepatokine, Metabolic syndrome",
author = "Masahiro Morita and Nadeem Siddiqui and Sakie Katsumura and Christopher Rouya and Ola Larsson and Takeshi Nagashima and Bahareh Hekmatnejad and Akinori Takahashi and Hiroshi Kiyonari and Mengwei Zang and Ren{\'e} St-Arnaud and Yuichi Oike and Vincent Gigu{\`e}re and Ivan Topisirovic and Mariko Okada-Hatakeyama and Tadashi Yamamoto and Nahum Sonenberg",
year = "2019",
month = "4",
day = "16",
doi = "10.1073/pnas.1816023116",
language = "English (US)",
volume = "116",
pages = "7973--7981",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "16",

}

TY - JOUR

T1 - Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis

AU - Morita, Masahiro

AU - Siddiqui, Nadeem

AU - Katsumura, Sakie

AU - Rouya, Christopher

AU - Larsson, Ola

AU - Nagashima, Takeshi

AU - Hekmatnejad, Bahareh

AU - Takahashi, Akinori

AU - Kiyonari, Hiroshi

AU - Zang, Mengwei

AU - St-Arnaud, René

AU - Oike, Yuichi

AU - Giguère, Vincent

AU - Topisirovic, Ivan

AU - Okada-Hatakeyama, Mariko

AU - Yamamoto, Tadashi

AU - Sonenberg, Nahum

PY - 2019/4/16

Y1 - 2019/4/16

N2 - Whole-body metabolic homeostasis is tightly controlled by hormone-like factors with systemic or paracrine effects that are derived from nonendocrine organs, including adipose tissue (adipokines) and liver (hepatokines). Fibroblast growth factor 21 (FGF21) is a hormone-like protein, which is emerging as a major regulator of whole-body metabolism and has therapeutic potential for treating metabolic syndrome. However, the mechanisms that control FGF21 levels are not fully understood. Herein, we demonstrate that FGF21 production in the liver is regulated via a posttranscriptional network consisting of the CCR4–NOT deadenylase complex and RNA-binding protein tristetraprolin (TTP). In response to nutrient uptake, CCR4–NOT cooperates with TTP to degrade AU-rich mRNAs that encode pivotal metabolic regulators, including FGF21. Disruption of CCR4–NOT activity in the liver, by deletion of the catalytic subunit CNOT6L, increases serum FGF21 levels, which ameliorates diet-induced metabolic disorders and enhances energy expenditure without disrupting bone homeostasis. Taken together, our study describes a hepatic CCR4–NOT/FGF21 axis as a hitherto unrecognized systemic regulator of metabolism and suggests that hepatic CCR4–NOT may serve as a target for devising therapeutic strategies in metabolic syndrome and related morbidities.

AB - Whole-body metabolic homeostasis is tightly controlled by hormone-like factors with systemic or paracrine effects that are derived from nonendocrine organs, including adipose tissue (adipokines) and liver (hepatokines). Fibroblast growth factor 21 (FGF21) is a hormone-like protein, which is emerging as a major regulator of whole-body metabolism and has therapeutic potential for treating metabolic syndrome. However, the mechanisms that control FGF21 levels are not fully understood. Herein, we demonstrate that FGF21 production in the liver is regulated via a posttranscriptional network consisting of the CCR4–NOT deadenylase complex and RNA-binding protein tristetraprolin (TTP). In response to nutrient uptake, CCR4–NOT cooperates with TTP to degrade AU-rich mRNAs that encode pivotal metabolic regulators, including FGF21. Disruption of CCR4–NOT activity in the liver, by deletion of the catalytic subunit CNOT6L, increases serum FGF21 levels, which ameliorates diet-induced metabolic disorders and enhances energy expenditure without disrupting bone homeostasis. Taken together, our study describes a hepatic CCR4–NOT/FGF21 axis as a hitherto unrecognized systemic regulator of metabolism and suggests that hepatic CCR4–NOT may serve as a target for devising therapeutic strategies in metabolic syndrome and related morbidities.

KW - CCR4–NOT

KW - Deadenylase

KW - FGF21

KW - Hepatokine

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85064396751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064396751&partnerID=8YFLogxK

U2 - 10.1073/pnas.1816023116

DO - 10.1073/pnas.1816023116

M3 - Article

VL - 116

SP - 7973

EP - 7981

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 16

ER -